Recent News

• 06.03.2025 - Cartesian Therapeutics Announces New Employment Inducement Grants
• 05.30.2025 - Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
• 05.13.2025 - Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
• 05.08.2025 - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.02.2025 - Cartesian Therapeutics Announces New Employment Inducement Grants
• 04.08.2025 - Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Recent Filings

• 05.30.2025 - EX-99.1 EX-99.1
• 05.30.2025 - 8-K Current report
• 05.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 05.08.2025 - 8-K Current report
• 04.29.2025 - 8-K Current report
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.28.2025 - DEF 14A Other definitive proxy statements